Visus Therapeutics announced today that three novel presbyopia treatments achieved their improvement endpoints in a Phase 2 study. Seattle-based Visus’ Vivid Phase 2 study observed all three of the included investigational candidates achieve the endpoint of three lines of improvement in binocular near visual activity without losing one line of distance vision with a minimum […]
Optical/Ophthalmic
Ocular Therapeutix claims win as court invalidates drug delivery patent from Mati
Ocular Therapeutix (NSDQ:OCUL) announced today that an appeals court invalidated a drug delivery system patent held by Mati Therapeutics. The U.S. Court of Appeals for the Federal Circuit in Washington, D.C., invalidated the patent related to a drug delivery system containing dexamethasone, affirming the judgment made in June 2020 by the Patent Trial and Appeal […]
Gyroscope Therapeutics to receive investment from Sanofi worth up to $60M
Gyroscope Therapeutics announced today that it received a commitment from Sanofi (NYSE:SNY) to invest up to $60 million. London-based Gyroscope will receive a $40 million investment from Sanofi initially. That $40 million represents a premium to Gyroscope’s previous Series C financing, with the remaining $20 million to be invested contingent on a future qualifying investment […]
NovaBay Pharmaceuticals closes acquisition of Dermadoctor
NovaBay Pharmaceuticals (NYSE:NBY) announced today that it closed its previously announced acquisition of skincare treatment developer Dermadoctor. Emeryville, California-based NovaBay develops the Avenova antimicrobial lid and lash spray, the CelleRx clinical reset and the NeutroPhase skin and wound cleanser for wound healing, all formulated with its patented, pure, stable, pharmaceutical-grade hypochlorous acid. In September, the […]
Eyenovia enrolls first patient in Phase 3 trial for treating presbyopia
Eyenovia (NSDQ:EYEN) announced today that it enrolled the first patient in the second Phase 3 clinical trial for its MicroLine formulation. New York-based Eyenovia designed its MicroLine proprietary pilocarpine formulation for temporary improvement in near vision (presbyopia). The Vision-2 trial, a double-masked, placebo-controlled, cross-over superiority trial will treat 140 subjects with presbyopia, randomly assigning them […]
NovaBay prices $15M private placement
NovaBay Pharmaceuticals (NYSE:NBY) announced today that it entered into a securities purchase agreement, with proceeds of approximately $15 million. Emeryville, California-based NovaBay’s agreement with certain institutional investors occurred in connection with a private placement of 15,000 shares of a newly created Series B non-voting convertible preferred stock. The Series B preferred stock comes in at […]
FDA approves first nasally administered pharmaceutical treatment for dry eye
AptarGroup (NYSE:ATR) announced today that it received FDA approval for its nasal pump to deliver a pharmaceutical treatment for dry eye. Crystal Lake, Illinois–based Aptar said the patented Cartridge Pump System (CPS) is for the multidose delivery of preserved and non-preserved drug formulations. It has received approval as the device for delivering Oyster Point Pharma’s […]
FDA approves Genentech’s Susvimo drug-eluting eye implant
Genentech announced today that it received FDA approval for its Susvimo injection for treating macular degeneration (AMD). South San Francisco-based Genentech, a member of the Roche Group, designed its Susvimo ranibizumab injection (100 mg/mL) for intravitreal use via ocular implant for treating people with wet, or neovascular, age-related macular degeneration (AMD) who have previously responded […]
Ocular Therapeutix dry eye treatment trial fails to meet primary endpoint
Ocular Therapeutix (NSDQ:OCUL) announced today that its Phase 2 clinical trial for treating dry eye disease (DED) did not meet its primary endpoint. Bedford, Massachusetts-based Ocular Therapeutix’s U.S.-based, randomized, double-masked, multi-center, vehicle-controlled Phase 2 clinical trial evaluated OTX-CSI (cyclosporine intracanalicular insert) for treating DED by measuring signs and symptoms of DED in 140 subjects treated […]
Medicine-saving Nanodropper makes history in Minnesota Cup win
The Minnesota Cup has awarded its grand prize for innovative entrepreneurs to a student-led startup for the first time. Medical device developer Nanodropper took home top honors from the awards ceremony, held Monday at the University of Minnesota. “We have created an eyedrop bottle adaptor that will save billions in medication waste, one drop at […]
